Sjogren's Syndrome (SS) is a chronic autoimmune rheumatic disease with a particular predisposition for causing inflammation of the exocrine glands, mainly the salivary and lacrimal glands, including the nose, upper respiratory tract, oropharynx, and the vagina in women.
The immune system inappropriately attacks various cells, leading to the activation of the various pathway, resulting in inflammation. The main consequence of this inflammation is developing sicca symptoms because of the damage to salivary and tear glands, like dryness of the mucosal surfaces, principally in the mouth and eyes. Dry eyes and dry mouth are the most common symptoms.
SS is mainly classified into two types, that is, Primary Sjogren's syndrome and Secondary Sjogren's syndrome. Primary Sjogren syndrome happens in the absence of another original rheumatic disorder. On the other hand, Secondary Sjögren syndrome is related to another underlying rheumatic disease or systemic autoimmune disease (mainly systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or scleroderma). Despite its considerable prevalence, SS has devoted much less research interest, time, and effort than other close conditions. Various multicenter consortiums initiatives have increased awareness for SS leading to defining critical areas of development, ultimately leading to improved patient care.
Sjogren's Syndrome Epidemiological Segmentation
The Epidemiological Segmentation of Sjogren's Syndrome in 7MM from 2017 to 2030 is segmented as:-
- Diagnosed Prevalent Cases
- Gender-Specific Cases
- Type-Specific Cases
- Severity-Specific Cases
Sjogren's Syndrome Epidemiology
- The total prevalent cases in 7MM were 3,179,223
- The prevalent cases in Spain were 197,008
The market size of Sjogren's Syndrome in 7MM in 2017 was USD 1,699.8 Million.
Sjogren's Syndrome Emerging Drugs
The emerging drugs of the Sjogren's Syndrome market are
And many others.
Sjogren's Syndrome Key Players
The key players in the Sjogren's Syndrome market are
- Resolve Therapeutics
- Bristol Myers Squibb
And many others.